U.S., Jan. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07353684) titled 'Adebrelimab, Apatinib & SOX for Conversion Therapy in Advanced Gastric/GEJ Cancer' on March 10, 2025.
Brief Summary: This is a prospective, single-center, single-arm, open phase II clinical study. Forty-nine participants with pathologically or cytologically confirmed gastric cancer or gastroesophageal junction cancer are scheduled to be enrolled in this study. All participants will be treated with 2 to 8 cycles of adebrelimab, apatinib, oxaliplatin, and tigio before surgery. Participants will evaluate the treatment effect after every 2 cycles of medication. By the investigator assessment as an operable subject, apatinib was disconti...